• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ImmuCell Hires Chief Financial Officer

    4/7/25 9:00:00 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ICCC alert in real time by email

    PORTLAND, Maine, April 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has hired Timothy C. Fiori to serve as its Chief Financial Officer.

    Mr. Fiori brings to ImmuCell approximately 24 years of finance and commercial operating experience with IDEXX Laboratories in Westbrook, Maine. He is a 2001 graduate of the University of Maine, Orono with a B.S in Finance. He lives in Raymond, Maine with his wife, Rachel, and enjoys many outdoor activities.

    "I am excited to join the ImmuCell leadership team at such a pivotal time in the Company's development," commented Mr. Fiori. "The product portfolio has tremendous proven value and great potential as we look to the future. I'm eager to start contributing immediately to the Company's growth and development."

    "Adding Tim's depth of experience and his great attitude to our team is a critical step in our ongoing growth plan," added Michael F. Brigham, President and CEO. "He can help us leverage our personnel, improve our standard costing and financial reporting systems and find new efficiencies in all aspects of our business, to touch on just a few of the anticipated impacts that I believe Tim will have on our business."

    About ImmuCell:

    ImmuCell Corporation's (NASDAQ:ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.

    Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):

    This Press Release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", "projects", "forecasts", "seeks" and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; future improvements to internal financial and accounting systems; projections of future financial or operational performance; future demand for our products; the timing and outcome of pending or anticipated applications for regulatory approvals; and any other statements that are not historical facts. These statements are intended to provide management's current expectations of future events as of the date of this earnings release, are based on management's estimates, projections, beliefs and assumptions as of the date hereof and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements; forward-looking statements include other risks and uncertainties detailed from time to time in filings we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to various factors. In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    Contacts:Michael F. Brigham, President and CEO

    ImmuCell Corporation

    (207) 878-2770



    Joe Diaz, Robert Blum and Joe Dorame

    Lytham Partners, LLC

    (602) 889-9700

    [email protected]
      


    Primary Logo

    Get the next $ICCC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICCC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ICCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: President and CEO Te Boekhorst Paul Francis Olivier bought $31,528 worth of Common Stock $0.10 par value per share (6,030 units at $5.23), increasing direct ownership by 163% to 9,738 units (SEC Form 4)

    4/A - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    12/4/25 4:11:39 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Te Boekhorst Paul Francis Olivier bought $48,588 worth of Common Stock $0.10 par value per share (9,785 units at $4.97) (SEC Form 4)

    4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    12/3/25 4:14:14 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Tomsche David Scott bought $15,554 worth of Common Stock $0.10 par value per share (3,266 units at $4.76), increasing direct ownership by 3% to 52,720 units (SEC Form 4)

    4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    11/28/25 8:12:55 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

    PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025. Product Sales Highlights: During the third quarter of 2025, product sales decreased by 8% to approximately $5.5 million compared to the third quarter of 2024.During the nine-month period ended September 30, 2025, product sales increased by 7% to approximately $20.0 million compared to the nine-month per

    11/13/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025

    PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2025 after the market closes on Thursday, November 13, 2025. The Company is planning to host a conference call the next morning, Friday, November 14, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-

    11/6/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Announces Onboarding of New CEO and Related Management Changes

    PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes. Effective November 1, 2025, Olivier te Boekhorst began serving as President and CEO of the Company, succeeding Michael F. Brigham. At its meeting on October 29, 2025, the Company's Board of Directors appointed Mr. te Boekhorst to the Board of Directors along with Timothy C. Fiori, CFO. Mr. Fiori joined ImmuCell as CFO in

    11/4/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    SEC Filings

    View All

    SEC Form 10-Q filed by ImmuCell Corporation

    10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)

    11/13/25 4:08:17 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)

    11/13/25 4:07:40 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition

    8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)

    11/4/25 4:08:55 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: President and CEO Te Boekhorst Paul Francis Olivier bought $31,528 worth of Common Stock $0.10 par value per share (6,030 units at $5.23), increasing direct ownership by 163% to 9,738 units (SEC Form 4)

    4/A - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    12/4/25 4:11:39 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Te Boekhorst Paul Francis Olivier bought $48,588 worth of Common Stock $0.10 par value per share (9,785 units at $4.97) (SEC Form 4)

    4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    12/3/25 4:14:14 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Tomsche David Scott bought $15,554 worth of Common Stock $0.10 par value per share (3,266 units at $4.76), increasing direct ownership by 3% to 52,720 units (SEC Form 4)

    4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    11/28/25 8:12:55 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    Leadership Updates

    Live Leadership Updates

    View All

    ImmuCell Announces Selection of its Next President and CEO

    PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has selected Olivier te Boekhorst as its next President and CEO. The Company anticipates a start date of November 1, 2025 for Mr. te Boekhorst. Mr. te Boekhorst is currently an Operating Partner at ARCHIMED, a global investment firm focused on human and animal healthcare industries, and serves as Chair of the Board of SeqCenter, a Next Generation Sequencing laboratory

    9/29/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Hires Chief Financial Officer

    PORTLAND, Maine, April 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has hired Timothy C. Fiori to serve as its Chief Financial Officer. Mr. Fiori brings to ImmuCell approximately 24 years of finance and commercial operating experience with IDEXX Laboratories in Westbrook, Maine. He is a 2001 graduate of the University of Maine, Orono with a B.S in Finance. He lives in Raymond, Maine with his wife, Rachel, and enjoys many outdoor activ

    4/7/25 9:00:00 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Appoints Bryan K. Gathagan to Board of Directors

    PORTLAND, Maine, June 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors. Mr. Gathagan is the owner and a managing member of broad Thinking, LLC, a management consulting firm and has 25 years of animal health experience. He is a founding member of Animalytix LLC and has served as its Chief Financial and Chief Technology Officer since it began operations in 2010. Prior to Animalytix

    6/21/23 4:05:22 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    Financials

    Live finance-specific insights

    View All

    ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

    PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025. Product Sales Highlights: During the third quarter of 2025, product sales decreased by 8% to approximately $5.5 million compared to the third quarter of 2024.During the nine-month period ended September 30, 2025, product sales increased by 7% to approximately $20.0 million compared to the nine-month per

    11/13/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025

    PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2025 after the market closes on Thursday, November 13, 2025. The Company is planning to host a conference call the next morning, Friday, November 14, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-

    11/6/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Announces Onboarding of New CEO and Related Management Changes

    PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes. Effective November 1, 2025, Olivier te Boekhorst began serving as President and CEO of the Company, succeeding Michael F. Brigham. At its meeting on October 29, 2025, the Company's Board of Directors appointed Mr. te Boekhorst to the Board of Directors along with Timothy C. Fiori, CFO. Mr. Fiori joined ImmuCell as CFO in

    11/4/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by ImmuCell Corporation

    SC 13D - IMMUCELL CORP /DE/ (0000811641) (Subject)

    8/27/24 4:32:59 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13D/A filed by ImmuCell Corporation (Amendment)

    SC 13D/A - IMMUCELL CORP /DE/ (0000811641) (Subject)

    4/16/21 3:21:48 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - IMMUCELL CORP /DE/ (0000811641) (Subject)

    2/4/21 11:27:59 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care